Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$20.61 USD
-0.41 (-1.95%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.63 +0.02 (0.10%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth C Momentum A VGM
Balance Sheet
Fiscal Year End for Arcturus Therapeutics Holdings Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 347 | 392 | 370 | 463 | 71 |
Receivables | 32 | 3 | 3 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 9 | 5 | 3 | 1 |
Total Current Assets | 387 | 403 | 379 | 468 | 74 |
Net Property & Equipment | 12 | 12 | 6 | 3 | 2 |
Investments & Advances | 0 | 0 | 1 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 0 | 0 |
Total Assets | 429 | 450 | 393 | 476 | 82 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 7 | 10 | 11 | 6 |
Current Portion Long-Term Debt | 0 | 61 | 22 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 32 | 30 | 24 | 21 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 45 | 29 | 43 | 18 | 8 |
Total Current Liabilities | 82 | 127 | 100 | 50 | 21 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 43 | 20 | 20 | 13 | 15 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 41 | 14 | 15 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 3 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 151 | 180 | 165 | 80 | 56 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 646 | 608 | 576 | 540 | 97 |
Retained Earnings | -368 | -338 | -347 | -144 | -72 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 279 | 270 | 228 | 397 | 26 |
Total Liabilities & Shareholder's Equity | 429 | 450 | 393 | 476 | 82 |
Total Common Equity | 279 | 270 | 228 | 397 | 26 |
Shares Outstanding | 26.70 | 26.50 | 26.30 | 24.40 | 15.10 |
Book Value Per Share | 10.43 | 10.20 | 8.68 | 16.25 | 1.71 |
Fiscal Year End for Arcturus Therapeutics Holdings Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 315 | 343 | 347 | 347 | 378 |
Receivables | 24 | 27 | 32 | 38 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 5 | 8 | 8 | 4 |
Total Current Assets | 347 | 376 | 387 | 393 | 385 |
Net Property & Equipment | 11 | 12 | 12 | 13 | 13 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 22 | 2 |
Total Assets | 389 | 419 | 429 | 458 | 431 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 14 | 9 | 5 | 18 | 14 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 35 | 35 | 32 | 29 | 29 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 42 | 72 | 45 | 41 | 48 |
Total Current Liabilities | 92 | 115 | 82 | 88 | 90 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 11 | 12 | 43 | 42 | 26 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 20 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 1 | 1 | 1 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 130 | 155 | 151 | 178 | 145 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 670 | 659 | 646 | 636 | 625 |
Retained Earnings | -412 | -395 | -368 | -356 | -340 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 259 | 264 | 279 | 280 | 285 |
Total Liabilities & Shareholder's Equity | 389 | 419 | 429 | 458 | 431 |
Total Common Equity | 259 | 264 | 279 | 280 | 285 |
Shares Outstanding | 26.90 | 26.90 | 26.70 | 26.60 | 26.50 |
Book Value Per Share | 9.61 | 9.81 | 10.43 | 10.53 | 10.76 |